Cargando…

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis

OBJECTIVE: Biological disease-modifying anti-rheumatic drugs (bDMARDs) represent an important advance in alleviating rheumatoid arthritis (RA), but their effect on rheumatic airway disease (AD) and interstitial lung disease (ILD) is still unclear. This study was performed to evaluate the association...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurata, Izumi, Tsuboi, Hiroto, Terasaki, Mayu, Shimizu, Masaru, Toko, Hirofumi, Honda, Fumika, Ohyama, Ayako, Yagishita, Mizuki, Osada, Atsumu, Ebe, Hiroshi, Kawaguchi, Hoshimi, Takahashi, Hiroyuki, Hagiwara, Shinya, Asashima, Hiromitsu, Kondo, Yuya, Matsumoto, Isao, Sumida, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630137/
https://www.ncbi.nlm.nih.gov/pubmed/30799358
http://dx.doi.org/10.2169/internalmedicine.2226-18
_version_ 1783435235747168256
author Kurata, Izumi
Tsuboi, Hiroto
Terasaki, Mayu
Shimizu, Masaru
Toko, Hirofumi
Honda, Fumika
Ohyama, Ayako
Yagishita, Mizuki
Osada, Atsumu
Ebe, Hiroshi
Kawaguchi, Hoshimi
Takahashi, Hiroyuki
Hagiwara, Shinya
Asashima, Hiromitsu
Kondo, Yuya
Matsumoto, Isao
Sumida, Takayuki
author_facet Kurata, Izumi
Tsuboi, Hiroto
Terasaki, Mayu
Shimizu, Masaru
Toko, Hirofumi
Honda, Fumika
Ohyama, Ayako
Yagishita, Mizuki
Osada, Atsumu
Ebe, Hiroshi
Kawaguchi, Hoshimi
Takahashi, Hiroyuki
Hagiwara, Shinya
Asashima, Hiromitsu
Kondo, Yuya
Matsumoto, Isao
Sumida, Takayuki
author_sort Kurata, Izumi
collection PubMed
description OBJECTIVE: Biological disease-modifying anti-rheumatic drugs (bDMARDs) represent an important advance in alleviating rheumatoid arthritis (RA), but their effect on rheumatic airway disease (AD) and interstitial lung disease (ILD) is still unclear. This study was performed to evaluate the association of the use of different bDMARDs with new-onset or worsening of RA-AD/ILD. METHODS: We performed a retrospective cohort study of RA patients who received bDMARDs and assessed their AD/ILD before and after drug initiation in our hospital over the past 10 years. We evaluated the serial changes in computed tomography (CT), classified patients according to AD/ILD progression, and analyzed associations between clinical characteristics and outcomes. RESULTS: We enrolled 49 patients. Thirty patients received tumor necrosis factor inhibitors (TNFis), 12 received abatacept (ABT), and the remaining 7 received tocilizumab (TCZ). Seventeen patients had ILD, 10 had AD, and 6 had both AD and ILD before the initiation of bDMARDs. New emergence or exacerbation of AD/ILD was observed in 18 patients after drug initiation, while the remaining 31 remained stable or improved. Multiple logistic regression analyses revealed that pre-existing AD was an independent risk factor against the emergence or exacerbation of RA-AD/ILD, and ABT use was a protective factor against it. CONCLUSION: Our study showed that pre-existing RA-AD is associated with future worsening of RA-AD/ILD, and ABT over other bDMARDs was associated with a better prognosis. Future studies to confirm our results are needed.
format Online
Article
Text
id pubmed-6630137
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-66301372019-07-17 Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis Kurata, Izumi Tsuboi, Hiroto Terasaki, Mayu Shimizu, Masaru Toko, Hirofumi Honda, Fumika Ohyama, Ayako Yagishita, Mizuki Osada, Atsumu Ebe, Hiroshi Kawaguchi, Hoshimi Takahashi, Hiroyuki Hagiwara, Shinya Asashima, Hiromitsu Kondo, Yuya Matsumoto, Isao Sumida, Takayuki Intern Med Original Article OBJECTIVE: Biological disease-modifying anti-rheumatic drugs (bDMARDs) represent an important advance in alleviating rheumatoid arthritis (RA), but their effect on rheumatic airway disease (AD) and interstitial lung disease (ILD) is still unclear. This study was performed to evaluate the association of the use of different bDMARDs with new-onset or worsening of RA-AD/ILD. METHODS: We performed a retrospective cohort study of RA patients who received bDMARDs and assessed their AD/ILD before and after drug initiation in our hospital over the past 10 years. We evaluated the serial changes in computed tomography (CT), classified patients according to AD/ILD progression, and analyzed associations between clinical characteristics and outcomes. RESULTS: We enrolled 49 patients. Thirty patients received tumor necrosis factor inhibitors (TNFis), 12 received abatacept (ABT), and the remaining 7 received tocilizumab (TCZ). Seventeen patients had ILD, 10 had AD, and 6 had both AD and ILD before the initiation of bDMARDs. New emergence or exacerbation of AD/ILD was observed in 18 patients after drug initiation, while the remaining 31 remained stable or improved. Multiple logistic regression analyses revealed that pre-existing AD was an independent risk factor against the emergence or exacerbation of RA-AD/ILD, and ABT use was a protective factor against it. CONCLUSION: Our study showed that pre-existing RA-AD is associated with future worsening of RA-AD/ILD, and ABT over other bDMARDs was associated with a better prognosis. Future studies to confirm our results are needed. The Japanese Society of Internal Medicine 2019-02-25 2019-06-15 /pmc/articles/PMC6630137/ /pubmed/30799358 http://dx.doi.org/10.2169/internalmedicine.2226-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Kurata, Izumi
Tsuboi, Hiroto
Terasaki, Mayu
Shimizu, Masaru
Toko, Hirofumi
Honda, Fumika
Ohyama, Ayako
Yagishita, Mizuki
Osada, Atsumu
Ebe, Hiroshi
Kawaguchi, Hoshimi
Takahashi, Hiroyuki
Hagiwara, Shinya
Asashima, Hiromitsu
Kondo, Yuya
Matsumoto, Isao
Sumida, Takayuki
Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
title Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
title_full Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
title_fullStr Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
title_full_unstemmed Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
title_short Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
title_sort effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630137/
https://www.ncbi.nlm.nih.gov/pubmed/30799358
http://dx.doi.org/10.2169/internalmedicine.2226-18
work_keys_str_mv AT kurataizumi effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT tsuboihiroto effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT terasakimayu effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT shimizumasaru effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT tokohirofumi effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT hondafumika effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT ohyamaayako effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT yagishitamizuki effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT osadaatsumu effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT ebehiroshi effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT kawaguchihoshimi effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT takahashihiroyuki effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT hagiwarashinya effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT asashimahiromitsu effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT kondoyuya effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT matsumotoisao effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis
AT sumidatakayuki effectofbiologicaldiseasemodifyingantirheumaticdrugsonairwayandinterstitiallungdiseaseinpatientswithrheumatoidarthritis